Propranolol Medical Valley
Non-selective beta-blocker (propranolol hydrochloride) — Film-coated tablets 10 mg
Quick Facts About Propranolol Medical Valley
Key Takeaways About Propranolol Medical Valley
- Broad clinical utility: Propranolol is approved for multiple indications including hypertension, angina, cardiac arrhythmias, migraine prevention, essential tremor, and the physical symptoms of anxiety, making it one of the most versatile cardiovascular drugs available
- Never stop abruptly: Sudden discontinuation can trigger rebound tachycardia, hypertension, worsening angina, or myocardial infarction, particularly in patients with underlying coronary artery disease. Dose tapering over 1–2 weeks is essential
- Contraindicated in asthma and severe COPD: As a non-selective beta-blocker, propranolol blocks β2 receptors in the bronchi, which can precipitate severe bronchospasm in patients with reversible airway disease
- Masks hypoglycemia symptoms: In patients with diabetes using insulin or sulfonylureas, propranolol can blunt the adrenergic warning signs of low blood sugar (tachycardia, tremor, anxiety), increasing the risk of unrecognized severe hypoglycemia
- First-line for migraine prevention: Propranolol is recommended by major neurological societies (AAN, AHS, EHF) as a first-choice prophylactic medication for migraine, reducing attack frequency by approximately 50% in responders
What Is Propranolol Medical Valley and What Is It Used For?
Propranolol Medical Valley is a prescription medication containing propranolol hydrochloride, a non-selective beta-adrenergic receptor antagonist (beta-blocker). It works by competitively blocking the effects of adrenaline (epinephrine) and noradrenaline (norepinephrine) on both β1 and β2 receptors, thereby reducing heart rate, blood pressure, myocardial oxygen demand, and peripheral adrenergic responses.
Propranolol Medical Valley is a generic formulation containing the same active ingredient as the original branded product Inderal, which was introduced by Sir James Black in 1964 and subsequently earned him the 1988 Nobel Prize in Physiology or Medicine. Propranolol was the prototype of the beta-blocker class and remains listed on the World Health Organization's Model List of Essential Medicines due to its broad therapeutic utility, well-characterized safety profile, and affordability.
The 10 mg strength is particularly suited to situations requiring lower starting doses, slow titration, flexible dosing schedules, or use in patients who are more sensitive to beta-blockade — including elderly patients, those with hepatic impairment, or individuals being treated for situational anxiety and essential tremor. Treatment should always be initiated under medical supervision, with the dose tailored to the individual indication, response, and tolerability.
Propranolol has an unusually broad spectrum of approved and evidence-based indications, reflecting the widespread distribution of beta-adrenergic receptors throughout the body. The principal clinical uses include:
- Hypertension (high blood pressure): Reduces systolic and diastolic pressure through decreased cardiac output, inhibition of renin release, and central sympathetic modulation
- Angina pectoris: Reduces myocardial oxygen demand by lowering heart rate and contractility, improving exercise tolerance and preventing ischemic episodes
- Cardiac arrhythmias: Particularly effective for supraventricular tachycardias, atrial fibrillation with rapid ventricular response, and catecholamine-sensitive arrhythmias
- Post-myocardial infarction: Reduces mortality and reinfarction rates when started in the early post-infarct period
- Migraine prophylaxis: Evidence-based first-line option for preventing recurrent migraine attacks
- Essential tremor: Reduces the amplitude of familial or benign postural tremor, improving daily functional tasks
- Hypertrophic obstructive cardiomyopathy (HOCM): Relieves dynamic outflow obstruction and improves symptoms
- Thyrotoxicosis: Controls adrenergic symptoms such as palpitations, tremor, and anxiety while definitive therapy takes effect
- Pheochromocytoma (with alpha-blockade): Adjunctive control of catecholamine-mediated tachycardia after adequate alpha-blockade has been established
- Portal hypertension: Reduces portal venous pressure and the risk of variceal bleeding in patients with cirrhosis
- Performance and situational anxiety (off-label): Blocks peripheral adrenergic symptoms such as tremor, tachycardia, and sweating
How Does Propranolol Work?
Propranolol exerts its pharmacological action through competitive, reversible blockade of both β1-adrenergic receptors (predominantly in the heart and kidneys) and β2-adrenergic receptors (in bronchial smooth muscle, vascular smooth muscle, liver, and pancreas). By preventing catecholamines from binding to these receptors, propranolol attenuates sympathetic nervous system activity across multiple organ systems.
In the heart, β1 blockade reduces heart rate (negative chronotropy), contractile force (negative inotropy), and conduction velocity through the atrioventricular node (negative dromotropy). Combined, these effects reduce cardiac output and myocardial oxygen demand, which explains propranolol's value in angina, arrhythmia, and heart failure contexts. In the kidneys, β1 blockade inhibits renin release from juxtaglomerular cells, reducing angiotensin II and aldosterone production and contributing to the antihypertensive effect.
Propranolol is also highly lipophilic, which allows it to cross the blood-brain barrier. This central penetration is thought to contribute to its efficacy in migraine prophylaxis, essential tremor, and performance anxiety, and it also explains some of the central side effects such as vivid dreams, sleep disturbances, and, rarely, depressive symptoms. Propranolol additionally possesses membrane-stabilizing (local anesthetic) activity at high concentrations, which is clinically relevant in cases of overdose.
Propranolol Medical Valley is a generic version of propranolol. Generic medicines are assessed by regulatory authorities such as the EMA, FDA, and MHRA against the reference product to ensure the same active ingredient, dose, dosage form, route of administration, and bioequivalence. This means they deliver the same therapeutic effect at equivalent quality standards as the originator brand.
What Should You Know Before Taking Propranolol Medical Valley?
Before starting Propranolol Medical Valley, your physician must evaluate your cardiovascular status, respiratory history, glucose metabolism, concurrent medications, and hepatic function. Propranolol is not appropriate for everyone, and certain pre-existing conditions — particularly asthma, advanced heart block, and severe bradycardia — represent absolute contraindications due to the risk of serious adverse outcomes.
Propranolol produces systemic effects that can be either therapeutic or harmful depending on the patient context. A careful medical history, physical examination, and sometimes baseline electrocardiogram or laboratory tests are required before initiating therapy. Patients should inform their healthcare provider about all current medications, supplements, herbal products, and any relevant medical conditions.
Contraindications
Propranolol Medical Valley must not be used in patients with any of the following conditions:
- Known hypersensitivity to propranolol or any excipient in the formulation
- Bronchial asthma or a history of bronchospasm — non-selective beta-blockade can provoke severe, potentially life-threatening airway constriction
- Severe chronic obstructive pulmonary disease (COPD) with a significant reversible component
- Cardiogenic shock
- Uncontrolled heart failure (acute decompensated state; stable heart failure on guideline-directed therapy is managed differently)
- Second- or third-degree atrioventricular (AV) block without a functioning pacemaker
- Sick sinus syndrome or severe sinus bradycardia (heart rate < 50 bpm)
- Severe hypotension (systolic blood pressure consistently < 90 mmHg)
- Untreated pheochromocytoma — beta-blockade without prior alpha-blockade can precipitate hypertensive crisis due to unopposed alpha-adrenergic stimulation
- Severe peripheral arterial disease, including advanced Raynaud's phenomenon
- Metabolic acidosis
- Prolonged fasting or cachexia in patients at risk of hypoglycemia
Warnings and Precautions
Several important warnings apply to patients taking propranolol and should be considered during every treatment course:
Abrupt withdrawal of propranolol, particularly in patients with coronary artery disease, can trigger rebound tachycardia, hypertension, worsening angina, myocardial infarction, or serious ventricular arrhythmias. When discontinuation is clinically indicated, the dose should be gradually tapered over at least 1–2 weeks under medical supervision.
Diabetes and hypoglycemia: Propranolol may mask the adrenergic warning signs of hypoglycemia (tachycardia, tremor, anxiety) while preserving sweating. Patients with diabetes on insulin or sulfonylureas should monitor blood glucose more frequently, particularly during dose titration or after illness. Propranolol may also prolong hypoglycemia by inhibiting hepatic gluconeogenesis and glycogenolysis mediated by β2 receptors.
Thyroid disease: Propranolol can mask clinical signs of hyperthyroidism such as tachycardia. Abrupt withdrawal in a patient with untreated hyperthyroidism may precipitate thyroid storm. Conversely, propranolol is useful as an adjunct in hyperthyroidism for rapid symptomatic control while definitive therapy (antithyroid drugs, radioiodine, or surgery) takes effect.
Hepatic impairment: Propranolol undergoes extensive hepatic first-pass metabolism via CYP2D6, CYP1A2, and CYP2C19. In advanced liver disease, bioavailability and plasma levels can rise substantially, increasing the risk of bradycardia, hypotension, and central nervous system side effects. Lower starting doses and careful titration are required.
Renal impairment: Propranolol is predominantly metabolized by the liver with minimal unchanged renal excretion, so dose adjustment is not usually necessary in mild to moderate renal impairment. Nevertheless, clinical monitoring is prudent in patients with severe renal dysfunction.
Peripheral arterial disease and Raynaud's phenomenon: Beta-blockade can worsen peripheral vasoconstriction through unopposed alpha-adrenergic activity. Patients with mild symptoms should be monitored for increased coldness, pallor, or pain in the extremities; in more severe disease propranolol should generally be avoided.
Psoriasis: Beta-blockers may exacerbate psoriasis or trigger the condition in predisposed individuals. The benefit–risk balance should be weighed carefully in affected patients.
Anesthesia and surgery: Patients on propranolol should inform anesthetists and surgeons before elective procedures. Continuation is usually preferred, but careful intraoperative monitoring for bradycardia and hypotension is essential. Concomitant use with certain anesthetics such as ether or methoxyflurane (rarely used today) can potentiate myocardial depression.
Depression: Propranolol is highly lipophilic and penetrates the central nervous system, where it has been associated with mood changes, sleep disturbances, and occasional reports of depression. Patients with a history of depression should be monitored closely. More hydrophilic beta-blockers (such as atenolol) may be preferable in susceptible individuals.
Allergic reactions: Patients with a history of severe anaphylactic reactions to any allergen may experience a more severe reaction while taking beta-blockers. Additionally, beta-blockers can reduce the effectiveness of epinephrine used to treat anaphylaxis.
Pregnancy and Breastfeeding
Propranolol crosses the placenta. Clinical data and registry studies have associated propranolol use in pregnancy with intrauterine growth restriction, fetal bradycardia, neonatal hypoglycemia, and transient neonatal β-blockade (bradycardia, hypotension, respiratory depression). Propranolol should be used during pregnancy only when the expected benefit clearly outweighs the potential risk, and the lowest effective dose should be selected.
When propranolol is used close to delivery, the neonate should be monitored for at least 48–72 hours for signs of beta-blockade such as bradycardia, hypoglycemia, and respiratory depression. Planning for delivery in a facility equipped to manage these complications is advisable. Any woman taking propranolol who becomes pregnant, or plans to conceive, should contact her physician for individualized assessment.
Propranolol is excreted into breast milk in small amounts. Although the relative infant dose is generally considered low, breastfed infants of mothers taking propranolol should be observed for signs of beta-blockade including sluggish feeding, lethargy, and bradycardia. A shared decision between mother and physician should weigh the importance of continued breastfeeding against the importance of maintaining maternal therapy.
How Does Propranolol Medical Valley Interact with Other Drugs?
Propranolol has numerous clinically important drug interactions. Combinations with other agents that slow the heart or lower blood pressure, alter hepatic metabolism via CYP2D6/CYP1A2/CYP2C19, or interfere with glycemic regulation can significantly affect safety and efficacy. Always inform your healthcare provider about every medication, supplement, and herbal product you are taking.
Because propranolol is heavily metabolized by the cytochrome P450 system, particularly CYP2D6 and CYP1A2, strong inducers or inhibitors of these enzymes can substantially alter plasma concentrations. In addition, pharmacodynamic interactions with other cardiovascular drugs can produce additive bradycardia, heart block, hypotension, or heart failure. Interactions are categorized below by clinical significance.
Major Interactions
The following interactions are clinically significant and may require dose adjustment, intensified monitoring, or avoidance of the combination:
| Drug / Drug Class | Mechanism | Clinical Effect | Recommendation |
|---|---|---|---|
| Verapamil, Diltiazem (non-dihydropyridine calcium channel blockers) | Additive negative inotropic, chronotropic, and dromotropic effects | Severe bradycardia, AV block, hypotension, acute heart failure | Avoid combination except under close specialist supervision |
| Clonidine | Abrupt withdrawal of clonidine while on beta-blocker leads to unopposed alpha-stimulation | Severe rebound hypertensive crisis | Taper propranolol first, then clonidine; never withdraw clonidine abruptly |
| Amiodarone, Class I antiarrhythmics (quinidine, flecainide, propafenone) | Additive cardiac electrophysiological depression; propafenone inhibits CYP2D6 | Bradycardia, conduction disturbances, increased propranolol exposure | Use with caution; monitor ECG and reduce dose if needed |
| Digoxin | Additive AV node conduction slowing | Excessive bradycardia, AV block | Monitor heart rate and PR interval; combination is useful but requires care |
| Insulin, sulfonylureas (glibenclamide, gliclazide) | Blunted adrenergic warning symptoms; inhibition of hepatic glucose recovery | Unrecognized severe or prolonged hypoglycemia | Frequent glucose monitoring; patient education on non-adrenergic hypoglycemia signs |
| Rifampicin | Strong CYP1A2/CYP2D6 inducer; reduces propranolol plasma levels substantially | Loss of therapeutic efficacy | Consider dose increase or alternative beta-blocker |
| Fluoxetine, Paroxetine, Bupropion (CYP2D6 inhibitors) | Inhibit CYP2D6 metabolism of propranolol, raising plasma levels | Enhanced beta-blockade, bradycardia, hypotension | Start with low dose and monitor heart rate and blood pressure |
| Ergotamine derivatives | Additive vasoconstriction via unopposed alpha-receptor activity | Severe peripheral vasoconstriction, ischemia | Avoid combination |
Minor and Moderate Interactions
The following interactions are less severe but still clinically relevant and should be monitored in routine practice:
| Drug / Drug Class | Effect | Recommendation |
|---|---|---|
| NSAIDs (ibuprofen, naproxen, diclofenac, indometacin) | May reduce antihypertensive effect through sodium retention and prostaglandin inhibition | Monitor blood pressure; avoid prolonged high-dose NSAID use |
| Cimetidine | Inhibits hepatic metabolism, raising propranolol levels | Monitor for enhanced beta-blockade; consider alternative H2 blocker such as famotidine |
| Lidocaine | Propranolol reduces hepatic clearance of lidocaine, increasing toxicity risk | Reduce lidocaine dose; monitor for CNS and cardiac toxicity |
| Theophylline | Propranolol reduces theophylline clearance; mutual antagonism of bronchodilator effect | Avoid combination if possible, especially in airway disease |
| Warfarin | May modestly increase warfarin effect | Monitor INR more frequently when adding or stopping propranolol |
| Alcohol | May enhance hypotensive effect; chronic use affects metabolism | Limit to moderate intake; avoid binge drinking |
| Sympathomimetics (pseudoephedrine, epinephrine) | Unopposed alpha-activity may cause hypertension and reflex bradycardia | Use with caution; avoid decongestant cold remedies |
What Is the Correct Dosage of Propranolol Medical Valley?
The correct dose of Propranolol Medical Valley depends on the clinical indication, patient age, weight, and response. Treatment typically starts at a low dose and is gradually titrated upward. The 10 mg tablet is ideal for low-dose initiation, flexible titration, and situations requiring lower maintenance doses such as essential tremor or situational anxiety.
Propranolol Medical Valley tablets should be swallowed whole with water and can be taken with or without food, although administering the medication consistently in relation to meals helps maintain predictable plasma levels. The drug is typically administered two to four times daily because of its relatively short elimination half-life of 3–6 hours. For conditions requiring smooth 24-hour coverage, a modified-release preparation may be preferred; this 10 mg immediate-release formulation is most suitable for flexible or lower-dose regimens.
Adults
| Indication | Starting Dose | Maintenance Dose | Notes |
|---|---|---|---|
| Hypertension | 40 mg twice daily | 160–320 mg daily in divided doses | Titrate weekly as needed; consider modified-release for convenience |
| Angina pectoris | 40 mg 2–3 times daily | 120–240 mg daily in divided doses | Adjust to anginal symptoms, heart rate, and blood pressure |
| Cardiac arrhythmias | 10–40 mg 3–4 times daily | 30–160 mg daily | Dose depends on arrhythmia type and response |
| Migraine prophylaxis | 40 mg 2–3 times daily | 80–160 mg daily | Allow 4–8 weeks to assess efficacy |
| Essential tremor | 40 mg 2–3 times daily | 80–160 mg daily | May use 10–20 mg on demand for situational tasks |
| Thyrotoxicosis (symptomatic) | 10–40 mg 3–4 times daily | Titrate to symptom control | Adjunctive to definitive antithyroid therapy |
| Situational / performance anxiety (off-label) | 10–40 mg as a single dose 30–60 minutes before event | As needed | Test dose under medical supervision before first real use |
| Post-myocardial infarction (secondary prevention) | 40 mg 4 times daily for 2–3 days, then 80 mg twice daily | 160–240 mg daily | Started 5–21 days post-infarct in eligible patients |
Dose Titration Principle
Because individual pharmacokinetic variability is wide, propranolol should be titrated cautiously starting from a low dose such as 10–40 mg, increasing at weekly or biweekly intervals based on heart rate, blood pressure, and symptomatic response. The goal is to achieve the therapeutic effect at the lowest effective dose.
Children
Propranolol is used in pediatric practice under specialist supervision for selected indications including supraventricular arrhythmias, long QT syndrome, hypertrophic cardiomyopathy, and hemangioma of infancy (for which a specific oral solution formulation, Hemangiol, is licensed). The 10 mg tablet is generally not appropriate for infants. For children aged 1–18 years, dosing is weight-based — typically 0.25–1 mg/kg per dose, given 3–4 times daily, with careful heart rate and glucose monitoring. Use in neonates is reserved for hospital specialist settings.
Elderly
Elderly patients often have reduced hepatic clearance, lower lean body mass, and increased sensitivity to beta-blockade. A lower starting dose is recommended, such as 10–40 mg once or twice daily, with cautious titration and monitoring for bradycardia, hypotension, cognitive changes, and postural symptoms. The 10 mg strength is particularly well suited for elderly patients requiring gradual dose escalation.
Missed Dose
If you miss a dose of Propranolol Medical Valley, take it as soon as you remember, unless it is nearly time for your next scheduled dose. In that case, skip the missed dose entirely and continue with your regular schedule. Never take a double dose to compensate for a missed one, as this can cause excessive bradycardia and hypotension. If you frequently forget doses, consider discussing alternative administration strategies (e.g., pill organizers, modified-release preparations) with your healthcare provider.
Overdose
Propranolol overdose is a medical emergency. Due to the drug's high lipophilicity and membrane-stabilizing activity, overdose can cause severe bradycardia, refractory hypotension, heart block, cardiogenic shock, bronchospasm, hypoglycemia, seizures, and cardiac arrest. Seek immediate medical attention by calling your local emergency number if an overdose is suspected, even in the absence of symptoms.
In hospital, treatment is largely supportive and may include gastric decontamination (activated charcoal if ingestion is recent), intravenous fluids, atropine, glucagon (a specific inotropic reversal agent for beta-blocker overdose), high-dose insulin-euglycemic therapy, vasopressors, temporary transvenous pacing, and in severe refractory cases, intravenous lipid emulsion therapy or extracorporeal life support (ECMO). Early consultation with a poison control center or clinical toxicologist is advised.
Sudden discontinuation of propranolol — especially after long-term use in ischemic heart disease — can provoke life-threatening rebound angina, arrhythmia, or myocardial infarction. If therapy must be discontinued, the dose should be reduced gradually over at least 1 to 2 weeks, ideally under medical supervision.
What Are the Side Effects of Propranolol Medical Valley?
Most side effects of propranolol are predictable extensions of its pharmacology — reduced heart rate, lowered blood pressure, cold extremities, fatigue, and central nervous system effects such as vivid dreams. Serious adverse effects such as severe bradycardia, bronchospasm, and heart failure are uncommon but require urgent recognition and action.
Like all medicines, Propranolol Medical Valley can cause side effects, although not everyone experiences them. Adverse reactions have been extensively characterized over more than 50 years of clinical use and in large cardiovascular outcome trials involving hundreds of thousands of patients. Most side effects are mild, dose-related, and improve over the first few weeks of treatment.
Frequency definitions follow the standard international convention: very common (more than 1 in 10 patients), common (1 in 10 to 1 in 100), uncommon (1 in 100 to 1 in 1,000), rare (1 in 1,000 to 1 in 10,000), and very rare (fewer than 1 in 10,000).
Very Common Side Effects
- Fatigue, tiredness
- Cold hands and feet (peripheral vasoconstriction)
- Bradycardia (slow heart rate)
Common Side Effects
- Dizziness, lightheadedness
- Sleep disturbances, vivid dreams, nightmares
- Nausea, vomiting, diarrhea, or constipation
- Reduced exercise tolerance, breathlessness on exertion
- Mild bronchospasm (in predisposed individuals)
- Headache
- Dry eyes, blurred vision
- Reduced libido, erectile dysfunction
Uncommon Side Effects
- Heart failure exacerbation
- Hypotension (symptomatic low blood pressure)
- First-degree AV block on ECG
- Depression, mood changes
- Confusion, memory impairment
- Paresthesia (tingling in hands or feet)
- Purpura or easy bruising
- Worsening psoriasis
- Raynaud's phenomenon, worsening claudication
Rare / Very Rare Side Effects
- Second- or third-degree AV block
- Severe bronchospasm, asthma attack
- Hallucinations, psychotic symptoms
- Thrombocytopenia (low platelet count)
- Severe hypoglycemia (especially in children, diabetics, or during fasting)
- Skin reactions including rash, urticaria, lupus-like syndrome
- Hepatic dysfunction with elevated liver enzymes
- Peyronie's disease (reported with long-term use)
Contact your doctor or emergency services immediately if you experience: severe shortness of breath or wheezing, very slow or irregular heartbeat, fainting, chest pain, sudden swelling of the ankles or feet, signs of severe allergic reaction (swelling of the face, lips, tongue, or throat, difficulty breathing), severe dizziness when standing, confusion or severe mood changes, prolonged symptoms of low blood sugar, or cold and discolored extremities.
Multiple meta-analyses and landmark trials — including the Beta-Blocker Heart Attack Trial (BHAT), the Norwegian Multicenter Study, and the Medical Research Council trials — have demonstrated that the benefits of propranolol in appropriately selected patients (reduced mortality, prevention of reinfarction, improved migraine outcomes) far outweigh the typical side effect burden. Most adverse effects are reversible on dose reduction or discontinuation after tapering.
Patients should report any concerning symptoms to their healthcare provider rather than stopping the medication on their own. Many side effects improve within the first 4 weeks of therapy as the body adapts to beta-blockade. Dose reduction or switching to a cardioselective beta-blocker (such as bisoprolol or metoprolol) may be considered if side effects are persistent or troublesome.
How Should You Store Propranolol Medical Valley?
Propranolol Medical Valley should be stored at room temperature below 25°C (77°F), in its original packaging, protected from light and moisture. Keep out of reach and sight of children. Do not use after the expiry date printed on the packaging.
Proper storage ensures that propranolol maintains its declared potency and safety throughout its shelf life. Tablets should be kept in their original blister pack or container until use, which protects the active ingredient from humidity and light. Do not transfer tablets to unlabelled containers, as this may lead to confusion with other medications and risks exposure to air and moisture.
Storage in bathrooms or kitchens is not ideal because of fluctuating temperature and humidity. Choose a dry cupboard at a stable room temperature instead. Do not refrigerate or freeze propranolol tablets unless specifically instructed on the product packaging. The medicine should not be used after the expiry date printed on the carton and blister, which refers to the last day of the indicated month.
Unused or expired propranolol should not be discarded with household waste or flushed down the toilet. Return unused medicines to a pharmacy for safe disposal according to local regulations. This helps protect the environment and prevents accidental ingestion by children, pets, or other members of the household. If you notice any visible changes in the appearance of the tablets (discoloration, cracks, powder, or unusual odor), do not take them and consult your pharmacist.
What Does Propranolol Medical Valley Contain?
Each film-coated tablet of Propranolol Medical Valley 10 mg contains 10 mg of the active substance propranolol hydrochloride, together with a number of inactive excipients that contribute to tablet stability, appearance, and disintegration after ingestion.
Active Ingredient
The active ingredient is propranolol hydrochloride, at a dose of 10 mg per film-coated tablet. Propranolol hydrochloride is the hydrochloride salt of a small, synthetic, racemic non-selective beta-adrenergic blocker with the chemical formula C16H21NO2·HCl and a molecular weight of 295.8 g/mol. It appears as a white to off-white crystalline powder, soluble in water and ethanol. The pharmacologically active enantiomer responsible for most of the beta-blocking activity is the S-(−)-isomer.
Inactive Ingredients (Excipients)
The specific excipients may vary slightly between different manufacturers and product batches. Typical excipients present in propranolol 10 mg film-coated tablets include:
- Tablet core: Lactose monohydrate, microcrystalline cellulose, maize starch (pregelatinized), povidone, croscarmellose sodium, colloidal anhydrous silica, magnesium stearate
- Film coating: Hypromellose, titanium dioxide (E171), macrogol (polyethylene glycol), talc, and potentially a colorant such as iron oxide (E172) depending on the tablet color
Propranolol Medical Valley tablets contain lactose. Patients with rare hereditary problems of galactose intolerance, total lactase deficiency, or glucose-galactose malabsorption should not take this medicine. Patients who have been told by a doctor that they have an intolerance to some sugars should consult their physician before taking this medicinal product.
The film coating facilitates swallowing, protects the active ingredient from air and light, and masks the bitter taste of propranolol. The 10 mg tablets are small and round; the precise color and embossed markings depend on the manufacturer. Always verify that the appearance of the tablets matches the description provided in the package leaflet supplied with the product.
Frequently Asked Questions About Propranolol Medical Valley
Propranolol Medical Valley is a non-selective beta-blocker used to treat hypertension, angina pectoris, supraventricular and ventricular arrhythmias, migraine prophylaxis, essential tremor, hypertrophic obstructive cardiomyopathy, and symptoms of hyperthyroidism. It is also prescribed for post-myocardial infarction secondary prevention and used off-label for performance anxiety. By blocking beta-1 and beta-2 adrenergic receptors, it reduces heart rate, blood pressure, and many of the peripheral effects of adrenaline.
No. Abrupt discontinuation of propranolol can cause a rebound phenomenon, with increased heart rate, rising blood pressure, worsening angina, and in the worst case myocardial infarction or ventricular arrhythmia. This risk is especially high in patients with coronary artery disease. If your physician decides to stop treatment, the dose should be gradually reduced over 1–2 weeks. Never stop propranolol on your own without medical guidance.
Alcohol should be consumed only in moderation while taking propranolol. Alcohol can enhance the blood-pressure-lowering effect, leading to dizziness or fainting, particularly on standing up. It can also increase propranolol plasma levels and chronic heavy drinking may alter hepatic metabolism unpredictably. Occasional moderate consumption is usually acceptable, but binge drinking should be avoided. Discuss your personal situation with your doctor.
Modest weight gain of 1–2 kg has been reported with beta-blockers including propranolol. The mechanism likely involves a small reduction in basal metabolic rate, reduced thermogenesis, and mild effects on insulin sensitivity. Most patients stabilize within the first few months. If weight gain becomes clinically significant, discuss the issue with your healthcare provider — alternative antihypertensive classes can sometimes be considered.
Yes, propranolol is frequently prescribed off-label for situational or performance anxiety. It blocks the peripheral adrenergic symptoms of anxiety — tremor, palpitations, sweating, and shaky voice — without significant effects on cognition. A typical dose is 10–40 mg taken 30–60 minutes before the anticipated stressful event. It is not addictive and does not cause sedation, but a physician should first confirm that it is safe and appropriate for you.
Propranolol crosses the placenta and is excreted in small amounts into breast milk. In pregnancy, its use has been associated with intrauterine growth restriction, fetal bradycardia, and neonatal hypoglycemia, so it is used only when the benefit clearly outweighs the risk. Neonates should be monitored for 48–72 hours after delivery. Breastfed infants of mothers on propranolol should be observed for lethargy or poor feeding. Always consult your obstetrician or pediatrician for individualized guidance.
Heart rate and blood pressure effects appear within 1–2 hours of a single dose. Maximum antihypertensive effect with regular dosing develops over 1–2 weeks. For migraine prophylaxis and essential tremor, clinical benefit may take 4–8 weeks to become fully apparent, which is why you should not discontinue therapy prematurely. For situational anxiety, a single dose taken 30–60 minutes before the event is typically sufficient.
References and Medical Sources
All information in this article is based on internationally recognized medical guidelines, peer-reviewed research, and official regulatory documentation. The following sources have been used:
- European Medicines Agency (EMA). Propranolol — Summary of Product Characteristics and European assessment reports. Last reviewed 2024.
- U.S. Food and Drug Administration (FDA). Inderal (propranolol hydrochloride) prescribing information. Reference ID current revision, 2024.
- World Health Organization (WHO). WHO Model List of Essential Medicines, 23rd List. 2023.
- British National Formulary (BNF). Propranolol hydrochloride monograph. Joint Formulary Committee, London, 2024.
- Mancia G, et al. 2023 ESH Guidelines for the management of arterial hypertension. Journal of Hypertension. 2023;41(12):1874-2071.
- Hindricks G, et al. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation. European Heart Journal. 2021;42(5):373-498. DOI: 10.1093/eurheartj/ehaa612
- Silberstein SD, et al. Evidence-based guideline update: pharmacologic treatment for episodic migraine prevention in adults. Neurology. 2012;78(17):1337-1345.
- Zesiewicz TA, et al. Evidence-based guideline update: treatment of essential tremor. Neurology. 2011;77(19):1752-1755.
- Black JW. Drugs from emasculated hormones: the principle of syntopic antagonism. Nobel Lecture, 1988.
- The Beta-Blocker Heart Attack Study Group. A randomized trial of propranolol in patients with acute myocardial infarction. JAMA. 1982;247(12):1707-1714.
- Freemantle N, et al. Beta blockade after myocardial infarction: systematic review and meta regression analysis. BMJ. 1999;318(7200):1730-1737.
- Léauté-Labrèze C, et al. A Randomized, Controlled Trial of Oral Propranolol in Infantile Hemangioma. New England Journal of Medicine. 2015;372(8):735-746.
Editorial Team
This article has been written and reviewed by the iMedic Medical Editorial Team, which includes specialists in cardiology, neurology, and clinical pharmacology. All content follows international guidelines and is based on evidence level 1A — the highest level of medical evidence, derived from systematic reviews and meta-analyses of randomized controlled trials.
Independent panel of board-certified physicians who review all content according to international guidelines (ESC, AHA/ACC, NICE, WHO, BNF). Specialists in beta-blocker therapy, hypertension management, and cardiovascular pharmacology.
All medical information follows the GRADE evidence framework. No commercial funding or pharmaceutical company sponsorship. Content is reviewed and updated regularly based on the latest clinical evidence and guideline updates.